Inhibition of the sodium-glucose co-transporter SGLT2 by canagliflozin ameliorates diet-induced obesity by increasing intra-adipose sympathetic innervation.

Xuping YangQinhui LiuYanping LiYi DingYan ZhaoQin TangTong WuLei ChenShiyun PuShihai ChengJinhang ZhangZijing ZhangYa HuangRui LiYingnan ZhaoMin ZouXiongjie ShiWei JiangRui WangJinhan He

Published in: British journal of pharmacology (2021)

Chronic inhibition of SGLT2 increased energy consumption by increasing intra-adipose sympathetic innervation to counteract diet-induced obesity. The present study reveals a new therapeutic function for SGLT2 inhibitors in regulating energy homeostasis.

Keyphrases

insulin resistance
metabolic syndrome
weight loss
high fat diet induced
adipose tissue
type diabetes
weight gain
skeletal muscle
mouse model